Efficacy of Micro-Transplantation Consolidation Therapy for Patients with Acute Myeloid Leukemia after Complete Remission.
10.19746/j.cnki.issn.1009-2137.2021.02.002
- Author:
Li-Xiao SONG
1
;
Shan-Dong TAO
1
;
Yuan DENG
1
;
Yue CHEN
1
;
Yi-Han DING
1
;
Chun-Ling WANG
1
;
Liang YU
1
;
Bang-He DING
2
Author Information
1. Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China,E-mail: 13813348520@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Consolidation Chemotherapy;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Retrospective Studies;
Transplantation Conditioning;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(2):316-321
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of micro-transplantation in acute myeloid leukemia (AML).
METHODS:The clinical data of 13 adult AML patients who received micro-transplantation as consolidation therapy from July 2014 to October 2019 was retrospectively analyzed, and the adverse reactions and efficacy of micro-transplantation were followed up.
RESULTS:Eight patients received micro-transpantation were still in complete remission, 5 patients relapsed after micro-transplantation, 1 of them received umbilical cord blood micro-transplantation after remission by reinduction, and all of the 13 patients have survived till now. The median overall survival time was 13 months, and the median relapse-free survival time was 12 months. All 13 patients developed grade 2-4 hematological adverse reactions. The median recovery time of neutrophils and platesets was 13 (11-15) and 15 (13-17) days, respectively. None of the 13 patients developed acute or chronic graft versus host disease. Twelve patients suffered from different infections, however, there were no serious organ function injury complications happened.
CONCLUSION:The micro-transplomtation of HLA-incompatible stem cells derived from peripheral blood or umbilical and blood is an effective regimen for the consolidation therapy of AML, especially for the patients suffered from low and moderate risk of AML or the aged AML patients.
